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A B S T R A C T 
Herpes zoster is a dermatovirosis that occurs at different age. However, with the patients aged over 60 years it 
presents with a painful syndrome preceded, accompanied or lasting up to one year after fading away of the 
eruptions. Intake of B-group vitamins favourably influences on the restoration of sensory nerves being mainly 
affected and causing the protracted painful syndrome. Milgamma N preparation in the shape of capsules is a 
combination of 40mg of vit. Bi , of 90mg of vit. Вб, and of 250 у of vit. Bn and ensures an optimal intestinal re­
sorption. The authors followed-up dynamically the therapeutic effect of Milgamma N in capsules on the devel­
opment of skin lesions and painful syndrome in 15 patients (7 males and 8 females) with herpes zoster. The 
duration of the therapy was 4 weeks long. The following protocol was made use of: week one - two capsules 
three times daily and weeks two through four - three times one capsule daily. The dermatologic and neurologic 
status as well as the subjective evaluation of the therapeutic effect was monitored in all the patients. There was 
a complete or an almost complete remission in 13 patients (86,7% of the cases) after one-month treatment. The 
skin lesions underwent an involution during a period of 10-17 days. The one-month schedule for treatment of 
herpes zoster with Milgamma N proved to be effective in a moderate degree of a painful syndrome and most 
common localization of the eruptions. 
Key words: herpes zoster, Milgamma N , ganglionitis, pain evaluation, therapeutic protocol 
I N T R O D U C T I O N 
Herpes zoster is a demiatovirosis associated with an inten­
sive pain in the acute stage of the disease and, later on, with 
a protracted post-zoster neuralgia. The varicella-zoster vi­
rus is the causative agent of herpes zoster. The disease pres­
ents with a disseminated vesicular eruption and induces a 
durable and strained immunity. The virus persists in spinal 
ganglia at a latent state and becomes activated in case of im­
munity collapse. A grouped vesicular eruption with 
dermatome localization develops along the corresponding 
sensory nerve (2,4,5). The incidence rate reaches up to 
0,5-1,0% of the total population and demonstrates an out­
lined tendency towards an increase during the recent de­
cades. Relapses occur extraordinarily seldom, in 1-5% of 
the cases, predominantly in the patients with neoplasms and 
on maintenance immunosuppressive and cytostatic therapy 
(1,6,7,8). 
The painful syndrome precedes and accompanies, but in 
certain cases even lasts up to one year after fading away of 
Address for correspondence: 
5! Pavlov, Clin, of Dermatology and Venereology, Dept. of 
Infectious Diseases and Epidemiology, Prof. P. Stoyanov 
Medical University of Varna, 55 Marin Drinov St, BG-9002 
Varna, BULGARIA 
the skin lesions. Its intensity increases in parallel with age. It 
can be observed in 50-70% of the patients aged over 60 
years. It is manifested with a permanent searing pain, sud­
den pain attacks lasting several minutes, or dysesthesiae of 
acute shooting and piercing pains. Copying the painful syn­
drome represents the primary therapeutic task and, in prac­
tice, symptomatic means are exclusively used. 
It is well known that B-group vitamins participate directly 
in the metabolism of the neurons and myelin. Vitamin Bi 
(thiamin) is co-factor in the carbohydrate metabolism. In 
high doses, it exerts an analgetic and anticholinesterase ef­
fect. Vitamin B& (pyridoxin) is a co-enzyme involved in the 
metabolism of the amino acids. It is necessary for the nor­
mal functioning of the central and peripheral nervous sys­
tem. Vitamin В12 (cyancobalamine) participates in DNA 
and myelin synthesis while its deficit leads to axonal degen­
eration. 
Milgamma N preparation in capsules contains 40mg of 
oil-soluble benfotiamin, 90mg of vitamin Вб, and 250 у of 
vitamin B 1 2 . The oil-soluble benfotiamin is the active form 
of vitamin В1. It is by 2-3 times better resorbed than the wa­
ter-soluble vitamin Bi that is directly proportional to the 
dose applied. Benfotiamms broad biological availability is 
determined by its resistance towards the thiaminase, too 
(3,9). 
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objective of the present study is to dynamically fol-
•up the therapeutic effect of Milgamma N in capsules 
ted on the skin lesions and painful syndrome in the pa-
s with herpes zoster. 
M A T E R I A L AND M E T H O D S 
study covered 15 patients with herpes zoster. They 
: 7 males aged between 50 and 70 years (mean age of 
years) and 8 females aged between 33 and 75 years 
in age of 60,3 years). The duration of the treatment was 
:eks long. The following protocol was used: in the first 
с - two capsules three times daily and in the next three 
cs - one capsule three times daily. The localization of 
ruption was the following: herpes zoster intercostalis -
atients; herpes zoster brachialis - 2 patients, herpes 
r mandibularis, herpes zoster maxillaris, and herpes 
rfemoralis - one patient each. The pain was present in 
le patients. It preceded the eruption in two patients 
% ) but accompanied the eruption in the rest 13 pa-
.. Herpes zoster occurred in a female patient after mas-
my. The treatment with Milgamma N started on the 
lay after diagnosing the disease. Tomapyrin in a dose 
е tablet daily for 7 days was added in one female pa-
Gentamycin was i. m. administered for 7 days in two 
its (13,3%). 
I treatment in the form of ointment, unguent, and spray 
antibiotic drug was applied in all the patients. The der­
ates affected by the eruption were not treated with lo-
lesthetic drugs at all. The pain was assessed by the pa-
themselves according to a visual analogous scale (a 
Fied scale of McGill) where the complete absence of 
vas rated by 0 points but the extraordinary painfulness 
ated by 20 points. 
R E S U L T S AND D I S C U S S I O N 
esults from the evaluation of the pain during the 
: of treatment were presented on Fig. 1. 
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In the beginning of the disease the scores corresponding to a 
slight to moderate feeling of pain at rest (8-14 points) pre­
vailed which increased by one to three points concerning 
the responses about the pain intensity during movement. In 
three patients there was a response classifying the pain by 
the definition of'strong feeling of pain*. With another three 
patients the pain was valued as slight. The subjective com­
plaints decreased progressively in the course of treatment 
and the pain persisted two months after the onset of the dis­
ease only in a 73-year old patient. 
In contrast to the zoster neuralgia the blistering eruption 
covered some part of the innervation area of the affected 
neuron only. Skin changes corresponded to a slight up to a 
moderately severe form of the disease. Skin lesions under­
went an involution for 10-17 days. Clinically, post-lesional 
rounded spots and, at places, atrophic regions after the re­
moval of the excoriations could be observed. 
The prevailing of the cases with a complete or almost com­
plete remission at the end of one-month treatment with 
Milgamma N in capsules and the necessity to continue the 
treatment in two patients only could be considered as a 
proof for a significant clinical efficacy. No side effects re­
lated with the intake of this preparation were observed at all. 
C O N C L U S I O N S 
1. Milgamma N is a drug of choice for the treatment of her­
pes zoster ganglionitis. 
2. An one-month therapeutic protocol is sufficient in most 
common clinical forms characterized by a typical localiza­
tion, moderate expression of the lesions and painful syn­
drome as well as by a tendency towards involution of the 
dermatologicaJ symptoms. 
3. It seems appropriate to maintain a Milgamma N therapy 
longer than 4 weeks in the cases with protracted course of 
the disease necessitating a combination with analgetic 
drugs. 
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